RxDoctor Payments DataLook up a doctor →

Srinivas Tantravahi, MD

Hematology · Salt Lake City, UTNPI 1972742245

Payments from drug & device makers

$15,866,708in general payments, 2019–2025

Across 2,411 payments — averaging $6580.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12.4M
  • Karyopharm Therapeutics Inc.$1.6M
  • Incyte Corporation$708K
  • AbbVie$562K
  • Sumitomo Pharma America, Inc.$332K
  • E.r. Squibb & Sons, L.L.C.$167K
  • plus $81K from 11 others
$20,083in research payments, 2019–2025

Across 14 payments — averaging $1434.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$18K
  • Novartis Pharma AG$2K

What the payments were for

  • Consulting fees$65,38581%
  • Speaking & faculty fees$8,91311%
  • Travel & lodging$3,5384%
  • Food & beverage$2,8314%
  • Education$430%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$52,939
Medicare patients
149
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ScemblixAsciminib Hydrochloride44$1,602,982
JakafiRuxolitinib Phosphate78$1,264,115
IclusigPonatinib Hcl36$767,035
SprycelDasatinib58$631,586
OjjaaraMomelotinib Dihydrochloride18$493,028
BosulifBosutinib30$325,870
RevlimidLenalidomide14$247,817
Dasatinib11$86,180
VenclextaVenetoclax24$44,358
Posaconazole19$17,445
EliquisApixaban12$7,200
Cyclosporine ModifiedCyclosporine, Modified28$3,213
Danazol12$2,655
Deferasirox11$2,622
Imatinib Mesylate28$2,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisScemblix$12,418,721$1,602,98244 claims
Incyte CorporationJakafi$708,072$1,264,11578 claims
E.r. Squibb & Sons, L.L.C.Sprycel$167,138$631,58658 claims
GSKOjjaara$10,148$493,02818 claims
Bristol Myers SquibbRevlimid$39,193$247,81714 claims
AbbVieVenclexta, Gengraf$562,063$45,50242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Utahon file to place this against a meaningful peer group, so we don't.

Other hematology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →